Thromb Haemost 2012; 108(03): 427-434
DOI: 10.1160/TH12-04-0274
Theme Issue Article
Schattauer GmbH

A novel regulatory element between the human FGA and FGG genes

Richard J. Fish
1   Department of Genetic Medicine and Development, University of Geneva Medical Centre, Geneva, Switzerland
,
Marguerite Neerman-Arbez
1   Department of Genetic Medicine and Development, University of Geneva Medical Centre, Geneva, Switzerland
2   Service of Angiology and Haemostasis, University Hospital and Faculty of Medicine, Geneva, Switzerland
› Author Affiliations
Financial support: This work was funded by the Swiss National Science Foundation funding to M. N.-A. (grant:31003A-134967), the Société Académique de Genève, the Dr. Henri Dubois-Ferrière Dinu Lipatti Foundation, the Ernst and Lucie Schmidheiny Foundation and the Ernest Boninchi Foundation.
Further Information

Publication History

Received: 30 April 2012

Accepted after major revision: 11 July 2012

Publication Date:
25 November 2017 (online)

Summary

High circulating fibrinogen levels correlate with cardiovascular disease (CVD) risk. Fibrinogen levels vary between people and also change in response to physiological and environmental stimuli. A modest proportion of the variation in fibrinogen levels can be explained by genotype, inferring that variation in genomic sequences that regulate the fibri-nogen genes (FGA, FGB and FGG) may affect hepatic fibrinogen production and perhaps CVD risk. We previously identified a conserved liver enhancer in the fibrinogen gene cluster (CNC12), between FGB and FGA. Genome-wide Chromatin immunoprecipitation-sequencing (ChIP-seq) demonstrated that transcription factors which bind fibrinogen gene promoters also interact with CNC12, as well as two potential fibrinogen enhancers (PFE), between FGA and FGG. Here we show that one of the PFE sequences has potent hepatocyte enhancer activity. Using a luciferase reporter gene system, we found that PFE2 enhances minimal promoter- and FGA promoter-driven gene expression in hepatoma cells, regardless of its orientation with respect to the promoters. A region within PFE2 bears a short series of conserved nucleotides which maintain enhancer activity without flanking sequence. We also demonstrate that PFE2 is a liver enhancer in vivo, driving enhanced green fluorescent protein expression in transgenic zebrafish larval livers. Our study shows that combining public domain ChIP-seq data with in vitro and in vivo functional tests can identify novel fibrinogen gene cluster regulatory sequences. Variation in such elements could affect fibrinogen production and influence CVD risk.